Get started
Author

Manuel Valladares

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
2012 · Eduardo Díaz-Rubio, Auxiliadora Gómez-España, et al. · The Oncologist · 214
PDF
Irinotecan in Combination With Fluorouracil in a 48-Hour Continuous Infusion As First-Line Chemotherapy for Elderly Patients With Metastatic Colorectal Cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
2005 · Javier Sastre, Eugenio Marcuello, et al. · Journal of Clinical Oncology · 98
Circulating Tumor Cell Count Is a Prognostic Factor in Metastatic Colorectal Cancer Patients Receiving First-Line Chemotherapy Plus Bevacizumab: A Spanish Cooperative Group for the Treatment of Digestive Tumors Study
2012 · Javier Sastre, M. Luisa Maestro, et al. · The Oncologist · 91
Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition
2013 · Luis A. Aparicio, Vanessa Abella, et al. · Cellular and Molecular Life Sciences · 58
PDF
Clinical implications of epithelial cell plasticity in cancer progression
2015 · Luis A. Aparicio, Moisés Blanco, et al. · Cancer Letters · 52
PDF
Biological influence of Hakai in cancer: a 10-year review
2012 · Luis A. Aparicio, Manuel Valladares, et al. · Cancer and Metastasis Reviews · 48
PDF
miR-203 Regulates Cell Proliferation through Its Influence on Hakai Expression
2012 · Vanessa Abella, Manuel Valladares, et al. · PLoS ONE · 40
PDF
First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study
2012 · Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, et al. · 25
Role of the microtubule-targeting drug vinflunine on cell-cell adhesions in bladder epithelial tumour cells
2014 · Luis A Aparicio, Raquel Castosa, et al. · BMC Cancer · 22
PDF
A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: The Pan-European Trial in Adjuvant Colon Cancer 2 study
2013 · Claus-Henning Köhne, Laurent Bedenne, et al. · European Journal of Cancer · 19
Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
2017 · Cristina Santos, Daniel Azuara, et al. · Molecular Cancer Therapeutics · 18
Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma
2006 · Margarita García, Xavier García del Muro, et al. · Melanoma Research · 18
A randomized phase II study of raltitrexed and gefitinib versus raltitrexed alone as second line chemotherapy in patients with colorectal cancer. (1839IL/0143)
2010 · José María Viéitez, Manuel Valladares, et al. · Investigational New Drugs · 13
Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
2017 · Fernando Rivera, Manuel Valladares, et al. · Journal of Medical Economics · 11
PDF
Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and KRAS, NRAS, BRAF, PI3KCA wild type (4WT). GEMCAD 1601 PIER trial.
2021 · Carlos Fernandez-Martos, Carles Pericay, et al. · Journal of Clinical Oncology · 3
Effect of pharmacogenetic-based selection of first-line chemotherapy on response rate and R0 surgery in metastatic CRC patients.
2016 · Albert Abad, Jose M Vieitez, et al. · Journal of Clinical Oncology · 2
Comparison of three molecular methods to detect mutations in KRAS, NRAS, BRAF and PIK3CA in metastatic colorectal cancer (mCRC).
2016 · Cristina Santos, Rocio Garcia-Carbonero, et al. · Journal of Clinical Oncology · 1
La causa del Dr. Esteban Corti, alias Curti
2025 · Valladares, Manuel · Revista del Archivo Nacional
Table S7 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
2023 · Cristina Santos, Daniel Azuara, et al.
Table S6 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
2023 · Cristina Santos, Daniel Azuara, et al.
Table S3 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
2023 · Cristina Santos, Daniel Azuara, et al.
Table S5 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
2023 · Cristina Santos, Daniel Azuara, et al.
Table S1 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
2023 · Cristina Santos, Daniel Azuara, et al.
Table S2 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
2023 · Cristina Santos, Daniel Azuara, et al.
Table S4 from Optimization of RAS/BRAF Mutational Analysis Confirms Improvement in Patient Selection for Clinical Benefit to Anti-EGFR Treatment in Metastatic Colorectal Cancer
2023 · Cristina Santos, Daniel Azuara, et al.
Works count: 32
Citation count: 733
H-index: 13
I10-index: 14
Year
Topic
Type